Earnings summaries and quarterly performance for RxSight.
Executive leadership at RxSight.
Board of directors at RxSight.
Research analysts who have asked questions during RxSight earnings calls.
SL
Steven Lichtman
Oppenheimer & Co. Inc.
5 questions for RXST
Also covers: ALC, ANGO, COO +12 more
DS
David Saxon
Needham & Company
4 questions for RXST
Also covers: ALC, ALGN, ATEC +11 more
Thomas Stephan
Stifel
4 questions for RXST
Also covers: ALC, GKOS, GMED +2 more
Adam Maeder
Piper Sandler Companies
3 questions for RXST
Also covers: ABT, AXNX, EW +13 more
DA
Danielle Antalffy
UBS Group AG
3 questions for RXST
Also covers: ABT, ATRC, BAX +15 more
LB
Larry Biegelsen
Wells Fargo & Company
3 questions for RXST
Also covers: ABT, ALC, AXNX +25 more
Alan
Morgan Stanley
2 questions for RXST
Also covers: IART, MT
AP
Anthony Petrone
Mizuho Group
2 questions for RXST
Also covers: ADMA, ALC, AXGN +24 more
CB
Craig Bijou
Bank of America Securities
2 questions for RXST
Also covers: BLCO, COO, FNA +9 more
LH
Lei Huang
Wells Fargo
2 questions for RXST
Also covers: NVCR, PEN, SOLV
LL
Lilia-Celine Lozada
JPMorgan Chase & Co.
2 questions for RXST
Also covers: ATRC, BVS, CBLL +4 more
RM
Robert Marcus
JPMorgan Chase & Co.
2 questions for RXST
Also covers: ABT, BAX, BDX +21 more
Tom Stephan
Stifel
2 questions for RXST
Also covers: ALC, BLCO, OFIX
YL
Young Li
Jefferies
2 questions for RXST
Also covers: ALC, ARAY, ATEC +8 more
AR
Angela Runyararo Kumirai
UBS Group
1 question for RXST
DS
David Saxon
Needham & Company LLC
1 question for RXST
Also covers: IRTC
Patrick Wood
Morgan Stanley
1 question for RXST
Also covers: ALC, BDX, BLCO +20 more
Ryan Zimmerman
BTIG
1 question for RXST
Also covers: ALC, CARL, GEHC +24 more
SK
Simran Kaur
Wells Fargo & Company
1 question for RXST
Also covers: AXGN, HYPR, PODD
Recent press releases and 8-K filings for RXST.
RxSight Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance
RXST
Earnings
Guidance Update
Demand Weakening
- Q4 2025 sales were $32.6 million, a 19% year-over-year decrease, primarily due to lower LDD sales, resulting in a net loss of $9.2 million.
- Full-year 2025 sales totaled $134.5 million, an increase of 4% year-over-year, with a net loss of $38.9 million.
- The company concluded 2025 with approximately $228 million in cash equivalents and no debt.
- For full-year 2026, revenue guidance is set at $120 million to $135 million, implying an approximate 5% year-over-year decline at the midpoint, mainly due to lower LDD sales.
- Gross margin guidance for 2026 is 70%-72%, a decrease from 2025, reflecting the sell-through of higher-cost inventory.
3 days ago
RxSight Reports Q4 and Full-Year 2025 Results, Provides 2026 Guidance
RXST
Earnings
Guidance Update
Demand Weakening
- RxSight reported Q4 2025 sales of $32.6 million, a 19% year-over-year decrease, primarily due to lower Light Delivery Device (LDD) sales. Full-year 2025 sales reached $134.5 million, a 4% increase year-over-year, driven by a 12% increase in Light Adjustable Lens (LAL) sales which offset a 48% decrease in LDD revenue.
- In Q4 2025, LAL revenue accounted for an all-time high of 86% of total sales, contributing to a gross margin of 77.5%. The LDD install base grew 17% to 1,134 units by the end of 2025. The company ended 2025 with $228 million in cash equivalents and no debt.
- For full-year 2026, RxSight projects revenue between $120 million and $135 million, implying an approximate 5% year-over-year decline at the midpoint, mainly due to anticipated lower LDD sales.
- Gross margin guidance for 2026 is 70%-72%, a decrease from 2025 levels but consistent with 2024, attributed to the sell-through of higher-cost inventory. LAL unit growth is expected to be in the low single-digit range, with utilization stabilizing around 8 lenses per LDD per month.
3 days ago
RxSight Reports Q4 and Full Year 2025 Financial Results and Provides 2026 Guidance
RXST
Earnings
Guidance Update
Demand Weakening
- RxSight reported Q4 2025 sales of $32.6 million, a 19% year-over-year decrease, and full-year 2025 sales of $134.5 million, a 4% year-over-year increase.
- The company posted a net loss of $9.2 million (or $0.22 per share) for Q4 2025 and a net loss of $38.9 million (or $0.95 per share) for the full year 2025.
- Gross margin for Q4 2025 was 77.5%, and 76.6% for the full year 2025, primarily driven by a higher LAL revenue mix.
- For full-year 2026, RxSight provided revenue guidance of $120 million-$135 million, representing an approximate 5% year-over-year decline at the midpoint, and gross margin guidance of 70%-72%.
- The company anticipates Q1 2026 sales to be the lowest due to seasonality and challenging comparisons, with a projected rebound in total company sales growth in the second half of the year.
3 days ago
RxSight Reports Q4 and Full-Year 2025 Results, Issues 2026 Guidance
RXST
Earnings
Guidance Update
Demand Weakening
- Full-year 2025 global sales for RxSight, Inc. were $134.5 million, representing a 4% decrease compared to the prior year, primarily driven by a 48% decrease in Light Delivery Device (LDD) system sales, which offset a 12% increase in Light Adjustable Lens (LAL) revenue.
- In the fourth quarter of 2025, total revenue decreased by 19% year-over-year to $32.6 million.
- The company reported a net loss of $(38.9) million, or $(0.95) per share, for full-year 2025, and an adjusted net loss of $(7.3) million, or $(0.18) per share.
- As of December 31, 2025, RxSight held $228.1 million in cash, cash equivalents, and short-term investments.
- For full-year 2026, RxSight provided revenue guidance of $120.0 million to $135.0 million and gross margin guidance of 70% to 72%.
3 days ago
RxSight Announces New CFO and Strong Q4 2025 Sales
RXST
CFO Change
Revenue Acceleration/Inflection
- RxSight announced the appointment of Mark Wilterding as its new Chief Financial Officer.
- The company pre-announced fourth-quarter 2025 sales of $32.6 million, exceeding street estimates of $27.6 million.
- RxSight concluded 2025 with 12% year-over-year growth in procedures and a nearly 20% increase in its installed base.
- The company ended 2025 with approximately $225 million in cash.
Jan 13, 2026, 11:45 PM
RxSight Announces New CFO and Provides Q4 Sales Update
RXST
CFO Change
Guidance Update
Revenue Acceleration/Inflection
- RxSight announced Mark Wilterding as its new Chief Financial Officer.
- The company pre-announced fourth-quarter sales of $32.6 million, surpassing street estimates of $27.6 million.
- RxSight reported 12% year-over-year growth in procedures and a nearly 20% increase in its installed base for the year, ending with approximately $225 million in cash.
- The company holds an approximate 10% market share in the U.S. premium IOL market and is strategically focusing on increasing LAL utilization and international expansion.
Jan 13, 2026, 11:45 PM
RxSight Reports Strong Q4 2025 Sales and Appoints New CFO
RXST
CFO Change
Revenue Acceleration/Inflection
- RxSight reported fourth-quarter 2025 sales of $32.6 million, surpassing Street estimates of $27.6 million, primarily driven by Light Adjustable Lenses (LALs).
- The company announced the appointment of Mark Wilterding as its new Chief Financial Officer.
- RxSight finished 2025 with approximately 12% year-over-year growth in procedures and a nearly 20% increase in its installed base.
- The company holds an approximate 10-12% market share in the U.S. premium IOL market and ended 2025 with about $225 million in cash.
- Management is focused on increasing utilization of its high-margin LAL product within its existing installed base and expanding internationally, with LAL gross margins expected to be in the 80% range long-term.
Jan 13, 2026, 11:45 PM
RxSight Presents 2025 Preliminary Results and Growth Strategy
RXST
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- RxSight reported preliminary unaudited total revenue of $134.5 million for 2025, alongside 109,615 LAL Units sold and an LDD Installed Base of 1,134.
- The company has facilitated ~300,000 LAL Procedures since inception, with 1,100+ Ophthalmic Offices utilizing LDDs and 2,500+ surgeons trained.
- RxSight holds approximately 10% of the US Premium IOL Market and maintains a strong financial position with $225M+ in Cash, Cash Equivalents & ST Investments.
- Future growth is planned through utilization expansion, increased surgeon access, ongoing innovation, and entry into international markets.
Jan 13, 2026, 12:00 PM
RxSight Announces Preliminary Q4 and Full-Year 2025 Results, Appoints New CFO
RXST
Earnings
CFO Change
Guidance Update
- RxSight, Inc. announced preliminary unaudited fourth quarter 2025 revenue of approximately $32.6 million and full-year 2025 revenue of approximately $134.5 million, which exceeds its November guidance of $125 million to $130 million.
- The company's preliminary unaudited cash, cash equivalents and short-term investments as of December 31, 2025, are expected to be $228.1 million.
- Mark Wilterding has been appointed as the new Chief Financial Officer, effective January 11, 2026, replacing Shelley Thunen.
- Mr. Wilterding's compensation includes an annual base salary of $550,000, eligibility for an annual bonus of up to 65% of his base salary, and equity awards consisting of an option to purchase 258,770 shares and 163,528 restricted stock units.
Jan 12, 2026, 9:34 PM
RxSight Announces Preliminary Q4 and Full-Year 2025 Results, Appoints New CFO
RXST
Earnings
Guidance Update
CFO Change
- RxSight reported preliminary unaudited fourth quarter 2025 revenue of approximately $32.6 million and preliminary unaudited full-year 2025 revenue of approximately $134.5 million, exceeding its November guidance of $125 to $130 million.
- Operational highlights include the sale of 28,611 Light Adjustable Lenses (LALs) in Q4 2025 and 109,615 LALs for the full year, contributing to an installed base of 1,134 Light Delivery Devices (LDDs) as of December 31, 2025.
- Preliminary unaudited cash, cash equivalents and short-term investments were approximately $228.1 million as of December 31, 2025.
- Mark Wilterding has been appointed as the new Chief Financial Officer, effective January 11, 2026.
Jan 11, 2026, 2:30 PM
Quarterly earnings call transcripts for RxSight.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more